Lixumistat for Glioblastoma
(LixuWoO Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to determine the effect of Lixumistat in patients with newly diagnosed Glioblastoma.
Who Is on the Research Team?
Macarena De La Fuente, MD
Principal Investigator
University of Miami
Are You a Good Fit for This Trial?
This trial is for adults who have just been diagnosed with glioblastoma, a type of brain cancer. Participants should not have started any treatment for their tumor yet and must be healthy enough to take part as judged by the study team.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Lixumistat
Trial Overview
The study is testing a new drug called Lixumistat in two different groups of patients before they start standard treatment for glioblastoma. The goal is to see how the drug affects the tumor during this early 'window of opportunity.'
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants will receive up to 4 doses (or up to 6 if the participant's date of surgery is delayed by up to 2 days) oral doses of Lixumistat (600 mg per dose), once daily prior to undergoing standard-of-care neurosurgical tumor resection. Total participation duration is up to 5 months.
Participants will receive up to 4 doses (or up to 6 if the participant's date of surgery is delayed by up to 2 days) oral doses of Lixumistat (400 mg per dose), once daily prior to undergoing standard-of-care neurosurgical tumor resection. Total participation duration is up to 5 months.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Macarena De La Fuente, MD
Lead Sponsor
ImmunoMet Therapeutics, Inc.
Industry Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.